Unlocking the power of precision medicine: exploring the role of biomarkers in cancer management

IF 3.4 Q2 PHARMACOLOGY & PHARMACY

Future Journal of Pharmaceutical Sciences Pub Date : 2024-01-05 DOI:10.1186/s43094-023-00573-2

Dipak D. Gadade, Hariom Jha, Chetan Kumar, Farzan Khan

{"title":"Unlocking the power of precision medicine: exploring the role of biomarkers in cancer management","authors":"Dipak D. Gadade, Hariom Jha, Chetan Kumar, Farzan Khan","doi":"10.1186/s43094-023-00573-2","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Personalized or Precision medicine (PM) is a promising approach for the cancer treatment that tailors treatment to a patient's characteristics. Biomarkers are crucial for identifying the patients who are expected to derive greatest advantage from targeted therapy.</p><h3>Main body</h3><p>Here, various biomarkers, including genetic, epigenetic, protein, and metabolites, and their clinical significance, are discussed. The review provides insights into the use of biomarkers and their clinical significance in cancer treatment. There are several hurdles in use of PM in oncology, such as the complexity of tumor biology and heterogeneity, limited availability of biomarkers, high cost of targeted therapies, resistance to targeted therapies, and ethical and social issues.</p><h3>Conclusion</h3><p>The biomarkers play a crucial diagnostic role in the treatment of cancer. The review also acknowledges the challenges and limitations of personalized medicine which, if resolved, can be helpful in the management of cancer.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-023-00573-2","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-023-00573-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Personalized or Precision medicine (PM) is a promising approach for the cancer treatment that tailors treatment to a patient's characteristics. Biomarkers are crucial for identifying the patients who are expected to derive greatest advantage from targeted therapy.

Main body

Here, various biomarkers, including genetic, epigenetic, protein, and metabolites, and their clinical significance, are discussed. The review provides insights into the use of biomarkers and their clinical significance in cancer treatment. There are several hurdles in use of PM in oncology, such as the complexity of tumor biology and heterogeneity, limited availability of biomarkers, high cost of targeted therapies, resistance to targeted therapies, and ethical and social issues.

Conclusion

The biomarkers play a crucial diagnostic role in the treatment of cancer. The review also acknowledges the challenges and limitations of personalized medicine which, if resolved, can be helpful in the management of cancer.

查看原文本刊更多论文

释放精准医疗的力量：探索生物标志物在癌症管理中的作用

背景个性化或精准医学（PM）是一种很有前途的癌症治疗方法，它能根据患者的特点进行治疗。生物标志物对于确定有望从靶向治疗中获得最大优势的患者至关重要。正文本文讨论了各种生物标志物，包括基因、表观遗传、蛋白质和代谢物及其临床意义。综述深入探讨了生物标记物在癌症治疗中的应用及其临床意义。在肿瘤学中使用 PM 有几个障碍，如肿瘤生物学的复杂性和异质性、生物标志物的有限可用性、靶向疗法的高成本、靶向疗法的抗药性以及伦理和社会问题。本综述还承认了个性化医疗所面临的挑战和局限性，如果这些挑战和局限性得到解决，将有助于癌症的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

23 weeks

期刊介绍： Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.